Nemolizumab

From WikiMD's WELLNESSPEDIA

Nemolizumab




Synonyms CIM-331




Routes Subcutaneous injection



Metabolism Proteolytic enzymes



Legal status Investigational
Identifiers
CAS Number 1476039-58-3



ChemSpider none
UNII GN465U8B72
KEGG D11080










Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]

Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]

References[edit]

  1. H. Spreitzer."Neue Wirkstoffe - Nemolizumab".Österreichische Apothekerzeitung.27 March 2017;(7/2017)
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74".WHO Drug Information.2015;29(3)
    411.Full text.
  3. "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis".New England Journal of Medicine.2017;376(9)
    826–835.doi:10.1056/NEJMoa1606490.PMID:28249150.
  4. , Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma Full text, , Pharmabiz.com, 22 July 2016,



Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.